Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia (Interfant06)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2014 by Dutch Childhood Oncology Group.
Recruitment status was:  Recruiting
BFM Germany
CORS Monza Italy
Associazione Italiana Ematologia Oncologia Pediatrica
Australian and New Zealand Children's Oncology Group
BFM Austria
CLCG France Belgium Portugal
COALL Germany
CPH, Czech republic
DFCI consortium USA
Hong Kong
MD Anderson USA
NOPHO Scandinavian countries
PINDA, Chile
Seattle USA
UKCCSG United Kingdom
Information provided by (Responsible Party):
Dutch Childhood Oncology Group Identifier:
First received: October 22, 2007
Last updated: February 14, 2014
Last verified: February 2014

RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, methotrexate, leucovorin, and antithymocyte globulin before and after transplant may stop this from happening. It is not yet known which treatment regimen is most effective in treating acute leukemia.

PURPOSE: This randomized clinical trial is studying how well different therapies work in treating infants with newly diagnosed acute leukemia.

Condition Intervention
Biological: anti-thymocyte globulin
Drug: asparaginase
Drug: busulfan
Drug: cyclophosphamide
Drug: cyclosporine
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: etoposide
Drug: leucovorin calcium
Drug: melphalan
Drug: mercaptopurine
Drug: methotrexate
Drug: mitoxantrone hydrochloride
Drug: pegaspargase
Drug: prednisolone
Drug: prednisone
Drug: therapeutic hydrocortisone
Drug: thioguanine
Drug: vincristine sulfate
Procedure: allogeneic bone marrow transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Procedure: umbilical cord blood transplantation

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia

Resource links provided by NLM:

Further study details as provided by Dutch Childhood Oncology Group:

Primary Outcome Measures:
  • Disease-free survival

Secondary Outcome Measures:
  • Survival
  • Event-free survival
  • Event-free survival within each risk group (i.e., low-risk, medium-risk, or high-risk)

Estimated Enrollment: 445
Study Start Date: June 2007
Estimated Primary Completion Date: June 2014 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   up to 1 Year   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


Inclusion criteria:

  • Diagnosis of acute lymphoblastic leukemia (ALL) or biphenotypic leukemia meeting the following criteria:

    • Based on European Group for the Classification of Acute Leukemia (EGIL) diagnostic criteria
    • Newly diagnosed disease
    • Verified by morphology and confirmed by cytochemistry and immunophenotyping

      • Trephine biopsy is recommended (unless diagnosis can be confirmed by peripheral blood examination) in the event that bone marrow aspiration results in a "dry tap"
  • Must have MLL gene rearrangements documented by split-signal fluorescence in situ hybridization and meets 1 of the following risk criteria:

    • Low-risk disease, defined as all MLL germline cases
    • Medium-risk disease, defined by 1 of the following criteria:

      • MLL status unknown
      • MLL rearranged AND age > 6 months
      • MLL rearranged AND age < 6 months AND WBC < 300 x 10^9/L AND prednisone good response
    • High-risk disease, defined by MLL rearrangement AND meets the following criteria:

      • Age at diagnosis < 6 months (i.e., < 183 days)
      • WBC ≥ 300 x 10^9/L AND/OR prednisone poor response
  • Minimum donor and stem cell requirements for high-risk patients undergoing stem cell transplantation:

    • Donor meeting 1 of the following criteria:

      • HLA-identical sibling
      • Very well-matched related or unrelated donor
      • Must be HLA compatible in 10/10 or 9/10 alleles by 4 digit/allele high-resolution molecular genotyping
    • Stem cell source

      • Bone marrow (preferred source) OR peripheral blood stem cells of filgrastim [G-CSF]-stimulated donors OR cord blood

        • Highly-matched unrelated umbilical cord blood (UCB) (> 7/8 matches identified by high-resolution typing) accepted if a sibling donor is not able to donate bone marrow AND UCB with a sufficient number of nucleated cells (NCs) (i.e., > 1.5 x 10^7/kg recipient body weight [BW]) is cryopreserved
    • Must have ≥ 3 x 10^8 NCs/kg BW OR 3 x 10^6/kg BW CD34-positive cells available for transplantation
  • CNS or testicular leukemia at diagnosis allowed

Exclusion criteria:

  • Mature B-ALL, defined by the immunophenotypical presence of surface immunoglobulins or t(8;14) and breakpoint as in B-ALL
  • Presence of the t(9;22) (q34;q11) or bcr-abl fusion in the leukemic cells (if data are not known, patient still may be eligible)
  • Relapsed ALL


  • See Disease Characteristics


  • More than 4 weeks since prior systemic corticosteroids

    • Corticosteroids by aerosol are allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00550992

United States, Massachusetts
Children's Hospital Boston Recruiting
Boston, Massachusetts, United States, 02215
Contact: Lewis B. Silverman, MD    617-632-5285      
United States, Tennessee
St. Jude Children's Research Hospital Recruiting
Memphis, Tennessee, United States, 38105
Contact: Clinical Trials Office - St. Jude Children's Research Hospital    901-595-4644      
United States, Texas
M. D. Anderson Cancer Center at University of Texas Recruiting
Houston, Texas, United States, 77030-4009
Contact: Clinical Trials Office - M. D. Anderson Cancer Center at the U    713-792-3245      
United States, Washington
Children's Hospital and Regional Medical Center - Seattle Recruiting
Seattle, Washington, United States, 98105
Contact: Blythe Thomson, MD    206-987-2106      
St. Anna Children's Hospital Recruiting
Vienna, Austria, A-1090
Contact: Georg Mann, MD    43-1-4017-1250      
Hopital Universitaire Des Enfants Reine Fabiola Recruiting
Brussels, Belgium, 1020
Contact: Alice Ferster, MD    32-2-477-2678   
Czech Republic
University Hospital Motol Recruiting
Prague, Czech Republic, 150 06
Contact: Jan Stary, MD    420-2-2443-6401   
CHR Hotel Dieu Recruiting
Nantes, France, 44093
Contact: Francoise Mechinaud, MD    33-1-4249-9046      
University Medical Center Hamburg - Eppendorf Recruiting
Hamburg, Germany, D-20246
Contact: Gritta Janka-Schaub    49-404-2803-2580      
Medizinische Hochschule Hannover Recruiting
Hannover, Germany, D-30625
Contact: Martin Schrappe, MD, PhD    49-511-532-6713      
Nuovo Ospedale San Gerardo at University of Milano-Bicocca Recruiting
Monza, Italy, 20052
Contact: Andrea Biondi, MD    39-039-233-3661   
Erasmus MC - Sophia Children's Hospital Recruiting
Rotterdam, Netherlands, 3015 GJ
Contact: Rob Pieters, MD, MSC, PhD    31-10-463-6691   
United Kingdom
Great Ormond Street Hospital for Children Recruiting
London, England, United Kingdom, WC1N 3JH
Contact: Phil Ancliff, MD    44-20-7829-8831      
Sponsors and Collaborators
Dutch Childhood Oncology Group
BFM Germany
CORS Monza Italy
Associazione Italiana Ematologia Oncologia Pediatrica
Australian and New Zealand Children's Oncology Group
BFM Austria
CLCG France Belgium Portugal
COALL Germany
CPH, Czech republic
DFCI consortium USA
Hong Kong
MD Anderson USA
NOPHO Scandinavian countries
PINDA, Chile
Seattle USA
UKCCSG United Kingdom
Study Chair: Rob Pieters, MD, MSC, PhD Erasmus MC - Sophia Children's Hospital
Study Chair: Martin Schrappe, MD, PhD University of Schleswig-Holstein
  More Information

Responsible Party: Dutch Childhood Oncology Group Identifier: NCT00550992     History of Changes
Other Study ID Numbers: CDR0000570260
Study First Received: October 22, 2007
Last Updated: February 14, 2014

Keywords provided by Dutch Childhood Oncology Group:
untreated childhood acute lymphoblastic leukemia
T-cell childhood acute lymphoblastic leukemia
acute undifferentiated leukemia

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Antilymphocyte Serum
Hydrocortisone 17-butyrate 21-propionate
Cortisol succinate
Hydrocortisone acetate
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors processed this record on May 25, 2017